This site is intended for Healthcare professionals only.

Adding Vasopressin to catecholamine lowers AF risk in Shock

Adding Vasopressin to catecholamine lowers AF risk in Shock

In patients with distributive shock, the addition of vasopressin to catecholamine vasopressors compared with catecholamines alone was associated with a lower risk of atrial fibrillation, according to a new meta-analysis and systematic review published in the JAMA.

The study was conducted by  Emilie Belley-Côté, MD, McMaster University, Hamilton, Ontario, Canada, and colleagues, to determine whether treatment with vasopressin + catecholamine vasopressors compared with catecholamine vasopressors alone was associated with reductions in the risk of adverse events.

Vasopressin is an alternative to catecholamine vasopressors for patients with distributive shock (a condition due to excessive vasodilation, most frequently from severe infection). Blood pressure support with a noncatecholamine vasopressor may reduce stimulation of adrenergic receptors and decrease myocardial oxygen demand. Atrial fibrillation is common with catecholamines and is associated with adverse events, including mortality and increased length of stay (LOS).

Using the GRADE system, investigators analyzed data from 3088 patients (mean age, 61.1 years; 45.3% women) in 23 studies. Of these, 22 studies, including the 2016 VANISH trial, included patients with septic shock; 15 trials were not blinded, and 5 were published only as abstracts.

Overall, 13 trials studied vasopressin, 9 terlipressin, 1 selepressin, and 1 pituitrin. One three-group study compared vasopressin vs terlipressin vs norepinephrine alone.

Key findings:

  • In absolute terms, 68 fewer people per 1000 patients (95% CI, 36 – 98) experienced atrial fibrillation when vasopressin is added to catecholamines.
  • The addition of vasopressin was associated with a 33% reduction in the risk for atrial fibrillation compared with catecholamines alone (risk ratio [RR], 0.77; 95% CI, 0.67 – 0.88).
  • The crude rate of atrial fibrillation was 73% in the post–cardiac surgery population and 13% in the sepsis studies.
  • The relative effect of vasopressin was similar in sensitivity analyses of patients after cardiac surgery (RR, 0.77; 95% CI, 0.67 – 0.88) and those with sepsis (RR, 0.76; 95% CI, 0.55 – 1.05).

The finding was driven by the 2017 VANCS study, which carried 74.8% of the weight and was one of two trials in the analysis to evaluate vasoplegic shock after cardiac surgery.

 “Clinicians may need to revisit their practice and start using vasopressin more frequently or earlier,” Belley-Côté told | Medscape Cardiology. “It’s a bit early, but the evidence in our review definitely differs from what was in the previous Surviving Septic campaign; so I do expect these findings to impact recommendations.”

The meta-analysis is the first on this topic to examine atrial fibrillation as an outcome and one of few reviews to compare vasopressin plus catecholamines against the current standard, catecholamines alone, the authors note.

In this systematic review and meta-analysis, the addition of vasopressin to catecholamine vasopressors compared with catecholamines alone was associated with a lower risk of atrial fibrillation. Findings for secondary outcomes varied.

For more information click on the link: 10.1001/jama.2018.4528

The following two tabs change content below.
Medha Baranwal

Medha Baranwal

Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She can be contacted at Contact no. 011-43720751
Source: With inputs from JAMA

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted